Activation of pregnane X receptor and induction of MDR1 by dietary phytochemicals

Journal of Agricultural and Food Chemistry

Volumn 56, Issue 13, 2008, Pages 5366-5373

  Satsu, Hideo ^a   Hiura, Yuto ^a   Mochizuki, Keiichi ^a   Hamada, Mika ^a   Shimizu, Makoto ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

CYP3A4; Ginkgolide; MDR1; Pregnane X receptor; Tangeretin

Indexed keywords

ABCB1 PROTEIN, HUMAN; BIOLOGICAL PRODUCT; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; FLAVONE DERIVATIVE; GINKGOLIDE; GLYCOPROTEIN P; PLANT EXTRACT; PREGNANE X RECEPTOR; STEROID RECEPTOR; TANGERETIN;

ARTICLE; CHEMISTRY; DIET; DIET SUPPLEMENTATION; DRUG EFFECT; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; PROMOTER REGION; REPORTER GENE; TUMOR CELL LINE;

BIOLOGICAL PRODUCTS; CELL LINE, TUMOR; CYTOCHROME P-450 CYP3A; DIET; DIETARY SUPPLEMENTS; FLAVONES; GENE EXPRESSION; GENES, REPORTER; GINKGOLIDES; HUMANS; P-GLYCOPROTEIN; PLANT EXTRACTS; PROMOTER REGIONS (GENETICS); RECEPTORS, STEROID; TRANSCRIPTION, GENETIC;

EID: 47849122700     PISSN: 00218561     EISSN: None     Source Type: Journal    
DOI: 10.1021/jf073350e     Document Type: Article

References (45)

1. Zheng, K.; Trivedi, M.; Siahaan, T. J. Structure and function of the intercellular junctions: Barrier of paracellular drug delivery. Curr. Pharm. Des. 2006, 12, 2813-2824.
2. Xu, C.; Li, C. Y.; Kong, A. N. Induction of phase I, II, and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 2005, 28, 249268.
3. Kliewer, S. A.; Goodwin, B.; Willson, T. M. The nuclear pregnane X receptor: A key regulator of xenobiotic metabolism. Endocr. Rev. 2002, 23, 687-702.
4. Tirona, R. G.; Kim, R. B. Nuclear receptors and drug disposition gene regulation. J. Pharm. Sci. 2005, 94, 1169-1186.
5. Jones, S. A.; Moore, L. B.; Shenk, J. L.; Wisely, G. B.; Hamilton, G. A.; McKee, D. D.; Tomkinson, N. C.; LeCluyse, E. L.; Lambert, M. H.; Willson, T. M.; Kliewer, S. A.; Moore, J. T. The pregnane X receptor: A promiscuous xenobiotic receptor that has diverged during evolution. Mol. Endocrinol. 2000, 14, 27-39.
6. Raucy, J. L. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab. Dispos. 2003, 31, 533-539.
7. Staudinger, J. L.; Goodwin, B.; Jones, S. A.; Hawkins-Brown, D.; MacKenzie, K. I.; LaTour, A.; Liu, Y.; Klaassen, C. D.; Brown, K. K.; Reinhard, J.; Willson, T. M.; Koller, B. H.; Kliewer, S. A. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 3369-3374.
8. Dussault, I.; Lin, M.; Hollister, K.; Wang, E. H.; Synold, T. W.; Forman, B. M. Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J. Biol. Chem. 2001, 276, 33309-33312.
9. Kawana, K.; Ikuta, T.; Kobayashi, Y.; Gotoh, O.; Takeda, K.; Kawajiri, K. Molecular mechanism of nuclear translocation of an orphan nuclear receptor, SXR. Mol. Pharmacol. 2003, 63, 524-531.
10. Squires, E. J.; Sueyoshi, T.; Negishi, M. Cytoplasmic localization of pregnane X receptor and ligand-dependent nuclear translocation in mouse liver. J. Biol. Chem. 2004, 279, 49307-49314.
11. Watkins, R. E.; Wisely, G. B.; Moore, L. B.; Collins, J. L.; Lambert, M. H.; Williams, S. P.; Willson, T. M.; Kliewer, S. A.; Redinbo, M. R. The human nuclear xenobiotic receptor PXR: Structural determinants of directed promiscuity. Science (Washington, DC, U.S.) 2001, 292, 2329-2333.
12. Watkins, R. E.; Maglich, J. M.; Moore, L. B.; Wisley, J. B.; Noble, S. M.; Davis-Searles, P. R.; Lambert, M. H.; Kliewer, S. A.; Redinbo, M. R. 2.1 Å crystal structure of human PXR in complex with St. John's wort compound hyperforin. Biochemistry 2003, 42, 1430-1438.
13. Ohnishi, A.; Matsuo, H.; Yamada, S.; Takanaga, H.; Morimoto, S.; Shoyama, Y.; Ohtani, H.; Sawada, Y. Effect of furanocoumarin derivatives in grape fruit juice on the uptake of vinblastine by Caco-2 cells and on the activity of cytochrome P450 3A4. Br. J. Pharmacol. 2000, 130, 1369-1377.
14. Konishi, T.; Satsu, H.; Hatsugai, Y.; Aizawa, K.; Inakuma, T.; Nagata, S.; Sakuda, S.; Nagasawa, H.; Shimizu, M. Inhibitory effect of a bitter melon extract on the P-glycoprotein activity in intestinal Caco-2 cells: Monoglyceride as an active compound. Br. J. Pharmacol. 2004, 143, 379-387.
15. Wang, E.; Barecki-Roach, M.; Johnson, W. W. Elevation of P-glycoprotein function by a catechin in green tea. Biochem. Biophys. Res. Commun. 2002, 297, 412-418.
16. Moore, L. B.; Goodwin, B.; Jones, S. A.; Wisely, G. B.; Serabjit-Singh, C. J.; Willson, T. M.; Collins, J. L.; Kliewer, A. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 7500-7502.
17. Hennessy, M.; Kelleher, D.; Spiers, J. P.; Barry, M.; Kavanagh, P.; Back, D.; Mulcahy, F.; Feely, J. St. John's wort increases expression of P-glycoprotein: Implications for drug interactions. Br. J. Clin. Pharmacol. 2002, 53, 75-82.
18. Hartley, D. P.; Dai, X.; Yabut, J.; Chu, X.; Cheng, O.; Zhang, T.; He, Y. D.; Roberts, C.; Ulrich, R.; Evers, R.; Evans, D. C. Identification of potential pharmacological and toxicological targets differentiating structural analogue by a combination of transcriptional profiling and promoter analysis in LS-180 and Caco-2 adenocarcinoma cell lines. Pharmacogenet. Genomics 2006, 16, 579-599.
19. Geick, A.; Eichelbaum, M.; Burk, O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampicin. J. Biol. Chem. 2001, 276, 14581-14587.
20. Hamada, M.; Satsu, H.; Natsume, Y.; Nishiumi, S.; Fukuda, I.; Ashida, H.; Shimizu, M. TCDD-induced CYP1A1 expression, an index of dioxin toxicity, is suppressed by flavonoids permeated the human intestinal Caco-2 cell monolayers. J. Agric. Food Chem. 2006, 54, 8891-8898.
21. Zhai, S.; Dai, R.; Friedman, F. K.; Vestal, R. E. Comparative inhibition of human cytochromes P450 1A1 and 1A2 by flavonoids. Drug Metab. Dispos. 1998, 26, 989-992.
22. Ciolino, H. P.; Daschner, P. J.; Yeh, G. C. Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially. Biochem. J. 1999, 340, 715-722.
23. Ashida, H.; Fukuda, I.; Yamashita, T.; Kanazawa, K. Flavones and flavonols at dietary levels inhibit a transformation of aryl hydrocarbon receptor induced by dioxin. FEBS Lett. 2000, 476, 213-217.
24. Liang, Y. C.; Tsai, S. H.; Tsai, D. C.; Lin-Shiau, S. Y.; Lin, J. K. Suppression of inducible cyclooxygenase and nitric oxide syndiase through activation of peroxisome proliferator-activated receptor-gamma by flavonoids in mouse macrophages. FEBS Lett. 2001, 496, 12-18.
25. Kluth, D.; Banning, A.; Paur, I.; Blomhoff, R.; Brigelius-Flohe, R. Modulation of pregnane X receptor- and electrophile-responsive element-mediated gene expression by dietary polyphenolic compounds. Free Radical Biol. Med. 2007, 42, 315-325.
26. Kauffmann, H. M.; Pfannschmidt, S.; Zöller, H.; Benz, A.; Vorderstemann, B.; Webster, J. I.; Schrenk, D. Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. Toxicology 2002, 171, 137-146.
27. Backman, J. T.; Mäenpä, J.; Belle, D. J.; Wrighton, S. A.; Kivistö, K. T.; Neuvonen, P. J. Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation. Clin. Pharmacol. Ther. 2000, 67, 382-390.
28. Bracke, M. E.; Vyncke, B. M.; Van Larebeke, N. A.; Bruyneel, E. A.; De Bruyne, G. K.; De Pestel, G. H.; De Coster, W. J.; Espeel, M. F.; Mareel, M. M. The flavonoid tangeretin inhibits invasion of MO4 mouse cells into embryonic chick heart in vitro. Clin. Exp. Metastasis 1989, 7, 283-300.
29. Bracke, M. E.; Depypere, H. T.; Boterberg, T.; Van Marck, V.; Vennekens, K. M.; Vanluchene, E.; Nuytinck, M.; Serreyn, R.; Mareel, M. M. Influence of tangeretin on tamoxifen's therapeutic benefit in mammary cancer. J. Natl. Cancer Inst. 1999, 91, 354-359.
30. Slambrouck, S. V.; Parmar, V. S.; Sharma, S. K.; Bondt, B. D.; Fore, F.; Coopman, P.; Vanhoecke, B. W.; Boterberg, T.; Depypere, H. T.; Leclercq, G.; Bracke, M. E. Tangeretin inhibits extracellular-signal-regulated kinase (ERK) phosphorylation. FEBS Lett. 2005, 579, 1665-1669.
31. Ding, S.; Dudley, E.; Plummer, S.; Tang, J.; Newton, R. P.; Brenton, A. G. Quantitative determination of major active components in Ginkgo biloba dietary supplements by liquid chromatography/mass spectrometry. Rapid Commun. Mass Spectrom. 2006, 20, 2753-2760.
32. Mauri, P.; Migliazza, B.; Pietta, P. Liquid chromatography/electrospray mass spectrometry of bioactive terpenoids in Ginkgo biloba L. J. Mass. Spectrom. 1999, 34, 1361-1367.
33. Yoshikawa, T.; Naito, Y.; Kondo, M. Ginkgo biloba leaf extract: Review of biological actions and clinical applications. Antioxid. Redox Signaling 1999, 1, 469-480.
34. Grundman, M.; Grundman, M.; Delaney, P. Antioxidant strategies for Alzheimer's disease. Proc. Nutr. Soc. 2002, 61, 191-202.
35. Gertz, H. J.; Kiefer, M. Review about Ginkgo biloba special extract EGb 761 (Ginkgo). Curr. Pharm. Des. 2004, 10, 261-264.
36. Park, Y. M.; Won, J. H.; Yun, K. J.; Ryu, J. H.; Han, Y. N.; Choi, S. K.; Lee, K. T. Preventive effect of Ginkgo biloba extract (GBB) on the lipopolysaccharide-induced expressions of inducible nitric oxide synthase and cyclooxygenase-2 via suppression of nuclear factor-kappaB in RAW 264.7 cells. Biol. Pharm. Bull. 2006, 29, 985-90.
37. Sugiyama, T.; Kubota, Y.; Shinozuka, K.; Yamada, S.; Yamada, K.; Umegaki, K. Induction and recovery of hepatic drug metabolizing enzymes in rats treated with Ginkgo biloba extract. Food Chem. Toxicol. 2004, 42, 953-957.
38. Tabb, M. M.; Sun, A.; Zhou, C.; Grun, F.; Errandi, J.; Romero, K.; Pham, H.; Inoue, S.; Mallick, S.; Lin, M.; Forman, B. M.; Blumberg, B. Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J. Biol. Chem. 2003, 278, 43919-43927.
39. Teng, S.; Piquette-Miller, M. The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice. J. Pharmacol. Exp. Ther. 2005, 312, 841-848.
40. Gu, X.; Ke, S.; Liu, D.; Sheng, T.; Thomas, P. E.; Rabson, A. B.; Gallo, M. A.; Xie, W.; Tian, Y. Role of NF-kappaB in regulation of PXR-mediated gene expression: A mechanism for the suppression of cytochrome P450 3A4 by proinflammatory agents. J. Biol. Chem. 2006, 281, 17882-17889.
41. Zhou, C.; Tabb, M. M.; Nelson, E. L.; Grun, F.; Verma, S.; Sadatrafiei, A.; Lin, M.; Mallick, S.; Forman, B. M.; Thummel, K. E.; Blumberg, B. Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J. Clin. Invest. 2006, 116, 2280-2289.
42. Fojo, A.; Akiyama, S.; Gottesman, M. M.; Pastan, I. Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res. 1985, 45, 3002-3007.
43. Schinkel, A. H.; Jonker, J. W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv. Drug Delivery Rev. 2003, 55, 3-29.
44. Vilaboa, N. E.; Galan, A.; Troyano, A.; Blas, E.; Aller, P. Regulation of multidrug resistance 1 (MDR1)/P-glycoprotein gene expression and activity by heat-shock transcription factor 1 (HSF1). J. Biol. Chem. 2000, 275, 24970-24976.
45. Tsukazaki, M.; Satsu, H.; Mori, A.; Konishi, Y.; Shimizu, M. Effects of tributyltin on barrier functions in human intestinal Caco-2 cells. Biochem. Biophys. Res. Commun. 2004, 315, 991-997.